Safrazine
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
[3-(1,3-benzodioxol-5-yl)-1-methyl-propyl]hydrazine
|
|
| Clinical data | |
| Routes of administration |
Oral |
| Legal status |
|
| Identifiers | |
| CAS Number | 33419-68-0 |
| ATC code | None |
| PubChem | CID 34042 |
| ChemSpider | 31375 |
| UNII | F5G0P5378C |
| Synonyms | 4-benzo[1,3]dioxol-5-ylbutan-2-ylhydrazine; [3-(3,4-(methylenedioxy)phenyl)-1-butyl]hydrazine; 2-piperonylisopropylhydrazine |
| Chemical data | |
| Formula | C11H16N2O2 |
| Molar mass | 208.26 g/mol |
Safrazine (Safra) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was introduced as an antidepressant in the 1960s, but has since been discontinued.[1]
See also[edit]
References[edit]
- ^ Dr. Ian Morton; I.K. Morton; Judith M. Hall (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 251–. ISBN 978-0-7514-0499-9.
|
|
|
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
